{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:26:16Z","timestamp":1782444376322,"version":"3.54.5"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0221816","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T17:31:37Z","timestamp":1567186297000},"page":"e0221816","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-2576","authenticated-orcid":true,"given":"Alice","family":"Cl\u00e9ment-Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Tanguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"De La Lande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bontemps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lemanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Savignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Peignaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Reynaud-Bougnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Gobillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlia","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"pone.0221816.ref001","first-page":"963","article-title":"Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis","volume":"57","author":"M Relf","year":"1997","journal-title":"Cancer Res"},{"key":"pone.0221816.ref002","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer","volume":"357","author":"K Miller","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"pone.0221816.ref003","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1470-2045(16)00011-5","article-title":"Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study","volume":"17","author":"F Bertucci","year":"2016","journal-title":"The Lancet Oncology"},{"key":"pone.0221816.ref004","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(12)70049-9","article-title":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study","volume":"13","author":"J-Y Pierga","year":"2012","journal-title":"The Lancet Oncology"},{"key":"pone.0221816.ref005","doi-asserted-by":"crossref","first-page":"mdw665","DOI":"10.1093\/annonc\/mdw665","article-title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer","author":"R Bell","year":"2016","journal-title":"Annals of Oncology"},{"key":"pone.0221816.ref006","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","article-title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","volume":"14","author":"D Cameron","year":"2013","journal-title":"The Lancet Oncology"},{"key":"pone.0221816.ref007","doi-asserted-by":"crossref","first-page":"S1-03-S1-03","DOI":"10.1158\/0008-5472.SABCS13-S1-03","article-title":"Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab \u00b1 bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer","volume":"73","author":"D Slamon","year":"2013","journal-title":"Cancer Research"},{"key":"pone.0221816.ref008","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1200\/JCO.2012.41.9820","article-title":"Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non\u2013Small-Cell Lung Cancer: Results of a Phase I\/II Trial","volume":"30","author":"MA Socinski","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"pone.0221816.ref009","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","article-title":"Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer","volume":"24","author":"CH Crane","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"pone.0221816.ref010","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2009.21.8529","article-title":"Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411","volume":"27","author":"CH Crane","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"pone.0221816.ref011","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2011.10.060","article-title":"A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417","volume":"83","author":"TE Schefter","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"pone.0221816.ref012","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2010.02.030","article-title":"Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer","volume":"80","author":"W Small","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"pone.0221816.ref013","doi-asserted-by":"crossref","first-page":"20140800","DOI":"10.1259\/bjr.20140800","article-title":"Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer","volume":"88","author":"V Pernin","year":"2015","journal-title":"Br J Radiol"},{"key":"pone.0221816.ref014","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.breast.2014.08.015","article-title":"Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer","volume":"23","author":"V Pernin","year":"2014","journal-title":"The Breast"},{"key":"pone.0221816.ref015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.canrad.2017.10.004","article-title":"Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study","volume":"22","author":"A Dautruche","year":"2018","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"pone.0221816.ref016","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0360-3016(79)90729-6","article-title":"Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast","volume":"5","author":"JR Harris","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"pone.0221816.ref017","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijrobp.2009.11.021","article-title":"Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab","volume":"79","author":"S Goyal","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"pone.0221816.ref018","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-014-3166-5","article-title":"Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study","volume":"148","author":"J Jacob","year":"2014","journal-title":"Breast Cancer Research and Treatment"},{"key":"pone.0221816.ref019","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-06-2441","article-title":"Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization","volume":"13","author":"RPM Dings","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"pone.0221816.ref020","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/j.ijrobp.2011.09.002","article-title":"Phase II Study of Long-Term Androgen Suppression With Bevacizumab and Intensity-Modulated Radiation Therapy (IMRT) in High-Risk Prostate Cancer","volume":"82","author":"J Vuky","year":"2012","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"pone.0221816.ref021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2009.24.7353","article-title":"Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab","volume":"28","author":"DR Spigel","year":"2010","journal-title":"J Clin Oncol"},{"key":"pone.0221816.ref022","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus Radiotherapy\u2013Temozolomide for Newly Diagnosed Glioblastoma","volume":"370","author":"OL Chinot","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"pone.0221816.ref023","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(11)70303-5","article-title":"Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial","volume":"13","author":"NY Lee","year":"2012","journal-title":"The Lancet Oncology"},{"key":"pone.0221816.ref024","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","article-title":"Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation","volume":"70","author":"D Miles","year":"2017","journal-title":"European Journal of Cancer"},{"key":"pone.0221816.ref025","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ctrv.2014.05.006","article-title":"A systematic review of bevacizumab efficacy in breast cancer","volume":"40","author":"I K\u00fcmler","year":"2014","journal-title":"Cancer Treatment Reviews"},{"key":"pone.0221816.ref026","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2017.10.018","article-title":"Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer","volume":"90","author":"D Miles","year":"2018","journal-title":"European Journal of Cancer"},{"key":"pone.0221816.ref027","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2008.19.5396","article-title":"Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy","volume":"27","author":"R Le Scodan","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0221816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:46:57Z","timestamp":1664239617000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0221816"}},"subtitle":[],"editor":[{"given":"Susan L.","family":"Mcgovern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0221816","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]}}}